Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

AIMS: Dapagliflozin is a selective inhibitor of sodium glucose co‐transporter 2 (SGLT2). This study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with type 2 diabetes (T2D) and moderate renal impairment (estimated glomerular filtration rate [eGFR], 45–59 mL/min/1.73 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Fioretto, Paola, Del Prato, Stefano, Buse, John B., Goldenberg, Ronald, Giorgino, Francesco, Reyner, Daniel, Langkilde, Anna Maria, Sjöström, C. David, Sartipy, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175614/
https://www.ncbi.nlm.nih.gov/pubmed/29888547
http://dx.doi.org/10.1111/dom.13413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175614/
https://www.ncbi.nlm.nih.gov/pubmed/29888547
http://dx.doi.org/10.1111/dom.13413

Ejemplares similares